Inclusive Dialogue and Compromise Needed to Address Major Issues Impacting Society Today, Reveals International Survey from Philip Morris International
The results of a new international survey released today by Philip Morris International Inc. (PMI) (NYSE: PM) reveal that citizens worldwide are frustrated by divisive and exclusionary approaches to policymaking. More than eight in ten adults surveyed worldwide (82 percent) believe the best solutions to critical global challenges can be found not at the extremes but in the middle ground. Conducted by independent research firm Povaddo for PMI, the survey of more than 44,000 adults in 22 countries shows strong agreement among respondents (88 percent) that when making decisions that affect the lives of a significant portion of the population, leaders must listen to and advocate for the people they represent.
The survey results show support for a balanced approach to tobacco regulation, one that brings together all voices and encourages incremental progress on harm reduction. Specifically, the survey found that:
- 77 percent agree that the too-often-ignored perspectives of those most directly impacted need to be included in regulatory discussions;
- 75 percent agree that societal expectations of total abstinence from substances such as nicotine and alcohol are not feasible, and so the government should take steps to reduce the harm of their use; and
- 72 percent agree that their governments need to consider the role alternative products can play in making their countries smoke-free.
“If we are to address the challenges we face as a society in a meaningful and expeditious way, a more balanced and inclusive approach is required,” said Gregoire Verdeaux, Senior Vice President, External Affairs. “This includes policy decisions that consider first and foremost the people who are most impacted—ensuring their voices are heard and their needs are met—and then bringing all relevant parties to the table, including subject matter experts, private companies, civil society leaders, and others who can contribute to solving the issues at hand.”
Despite increasingly polarized societies worldwide, the survey revealed a strong consensus that finding a middle ground on contentious issues can drive incremental policy change and enable progress:
- 90 percent of respondents believe that to solve the most pressing societal challenges, leaders need to consider all perspectives—even those that run counter to their own.
- 88 percent said they would be more likely to vote for leaders who listen to all sides of an issue and adopt sensible approaches that better the lives of ordinary people.
- Currently, less than a third of adults surveyed (31 percent) believe their views are reflected in the way their governments are addressing critical issues.
Additionally, the survey found that citizens are tired of waiting for change and are willing to compromise to make things happen:
- 76 percent believe leaders should pursue policy changes that allow for incremental progress on societal issues rather than hold out for sweeping changes that are harder to implement.
Finally, people want companies and business leaders to help drive change:
- 85 percent of respondents believe that citizens and companies working together will have a more meaningful impact.
- 77 percent welcome corporate involvement in addressing major issues.
Gregoire Verdeaux said: “In countries across the world, citizens are tired of policymaking logjams and eager for constructive change. In the area of tobacco harm reduction, PMI has long advocated for a sensible approach that prioritizes the interests of current adult smokers and public health. By having balanced and inclusive discussions about the science behind better alternatives and adopting a more people-centric approach, we can accelerate the end of cigarettes. More than a billion people continue to smoke. We must—and can—do better, and that starts with open, fact-based dialogue.”
For additional information and to access the full global data set, visit www.pmi.com/hearallvoices.
Survey Methodology
Povaddo conducted the online survey on behalf of PMI between February 5 and 23, 2022. The survey was fielded among 44,000+ general population adults aged 21 and older in 22 countries: Argentina, Brazil, Bulgaria, Colombia, Costa Rica, the Czech Republic, Dominican Republic, France, Germany, Greece, Italy, Japan, Malaysia, Mexico, the Philippines, Portugal, Serbia, South Africa, South Korea, Spain, the United Kingdom, and the United States. Around 2,000 interviews were conducted in each country (approximately equally split between adults who do and do not use nicotine-containing products). The data are weighted to be representative of the online population in each country on the following variables: age, gender, region, and nicotine use. The results are accurate to a margin of error of ±1 percent.
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of preclinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as modified risk tobacco products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of March 31, 2022, PMI’s smoke-free products are available for sale in 71 markets, and PMI estimates that approximately 12.7 million adults around the world, excluding Russia and Ukraine, have already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005283/en/
Contact information
Philip Morris International
David Fraser
Philip Morris International
T. +41 (0)79 843 8603
E. david.fraser@pmi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 11:00:00 EET | Press release
Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of annual net turnover. SWIFT SRG 2025 is another seismic update, representing the
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release
Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 08:00:00 EET | Press release
Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It proves a supplier has undergone an exhaustive audit of its governance, security controls, and operational processes. For Dutch financial institutions, this qualificatio
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 04:00:00 EET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
